AU2017301949B2 - Compounds, reagents, and uses thereof - Google Patents

Compounds, reagents, and uses thereof Download PDF

Info

Publication number
AU2017301949B2
AU2017301949B2 AU2017301949A AU2017301949A AU2017301949B2 AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2 AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2
Authority
AU
Australia
Prior art keywords
compound
subject
level
salt
kidney function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017301949A
Other languages
English (en)
Other versions
AU2017301949A1 (en
Inventor
Anne M. Evans
Qibo Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of AU2017301949A1 publication Critical patent/AU2017301949A1/en
Application granted granted Critical
Publication of AU2017301949B2 publication Critical patent/AU2017301949B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2017301949A 2016-07-28 2017-07-27 Compounds, reagents, and uses thereof Active AU2017301949B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367839P 2016-07-28 2016-07-28
US62/367,839 2016-07-28
PCT/US2017/044151 WO2018022866A1 (en) 2016-07-28 2017-07-27 Diagnostic methods, therapeutic agents and uses thereof

Publications (2)

Publication Number Publication Date
AU2017301949A1 AU2017301949A1 (en) 2019-01-31
AU2017301949B2 true AU2017301949B2 (en) 2021-09-23

Family

ID=59579921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017301949A Active AU2017301949B2 (en) 2016-07-28 2017-07-27 Compounds, reagents, and uses thereof

Country Status (8)

Country Link
US (1) US10865183B2 (cg-RX-API-DMAC10.html)
EP (1) EP3491004B1 (cg-RX-API-DMAC10.html)
JP (1) JP6987123B2 (cg-RX-API-DMAC10.html)
CN (1) CN109563127B (cg-RX-API-DMAC10.html)
AU (1) AU2017301949B2 (cg-RX-API-DMAC10.html)
CA (1) CA3032116A1 (cg-RX-API-DMAC10.html)
ES (1) ES2891088T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018022866A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3410115A1 (en) * 2013-05-14 2018-12-05 Metabolon, Inc. Tryptophan as a biomarkers for kidney function and methods using the same
US11182920B2 (en) * 2018-04-26 2021-11-23 Jerry NAM Automated determination of muscle mass from images
TWI669506B (zh) * 2018-07-06 2019-08-21 國軍桃園總醫院 計算腎絲球過濾率之方法
WO2021126158A1 (en) * 2019-12-16 2021-06-24 Hill's Pet Nutrition, Inc. Methods, kits and compositions for diagnosing and treating renal disease
CN114026427B (zh) * 2020-05-19 2023-11-17 深圳市中医院 诊断肾病的标志物以及诊断方法
AU2020480829A1 (en) 2020-12-07 2023-07-20 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
AU2022429891A1 (en) * 2021-12-27 2024-06-06 Société des Produits Nestlé S.A. Compositions and methods for diagnosing and treating chronic kidney disease
CN119355249A (zh) * 2024-09-20 2025-01-24 长沙都正生物科技股份有限公司 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物
WO2026120352A1 (en) * 2024-12-03 2026-06-11 Societe Des Produits Nestle Sa Estimating glomerular filtration rates in felines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186311A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
WO2015087985A1 (ja) * 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186311A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
WO2015087985A1 (ja) * 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROBERT G. FASSETT ET AL, "Biomarkers in chronic kidney disease: a review", KIDNEY INTERNATIONAL, (2011-10-01), vol. 80, no. 8, pages 806 - 821 *
SABINE GEBAUER ET AL, "Three-Dimensional Quantitative Structure-Activity Relationship Analyses of Peptide Substrates of the Mammalian H + /Peptide Cotransporter PEPT1", J. Med Chem, (2003-12-01), vol. 46, no. 26, pages 5725 - 5734 *
W L Mock ET AL, "Specificity and pH dependence for acylproline cleavage by prolidase", Journal of Biological Chemistry, (1990-11-15), pages 19600 - 19605 *

Also Published As

Publication number Publication date
JP2019531261A (ja) 2019-10-31
ES2891088T3 (es) 2022-01-26
WO2018022866A1 (en) 2018-02-01
EP3491004B1 (en) 2021-09-01
CN109563127A (zh) 2019-04-02
CA3032116A1 (en) 2018-02-01
US20190152907A1 (en) 2019-05-23
EP3491004A1 (en) 2019-06-05
US10865183B2 (en) 2020-12-15
AU2017301949A1 (en) 2019-01-31
JP6987123B2 (ja) 2021-12-22
CN109563127B (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
EP3491004B1 (en) Diagnostic methods, therapeutic agents and uses thereof
US20210116467A1 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
EP2222220B1 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
US11680042B2 (en) Compounds, reagents, and uses thereof
CN101374555A (zh) 神经衍生的生物分子体内代谢的检测方法
CA2775033C (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
US20220034865A1 (en) Diagnostic methods, therapeutic agents and uses thereof
WO2021232211A1 (zh) 诊断肾病的标志物以及诊断方法
US20230091848A1 (en) Disease detection and treatment based on phenylacetyl glutamine levels
WO2012007531A2 (en) Methods and compositions for diagnosing medical conditions
US20160195550A1 (en) Metabolism of sod1 in csf
Medina et al. Antiepileptic drugs affect lipid oxidative markers-neuroprostanes and F2-dihomo-isoprostanes-in patients with epilepsy: Differences among first-, second-, and third-generation drugs by UHPLC-QqQ-MS/MS
CA3059264A1 (en) Oxidized lipids as biomarkers for neuropathic pain
JPWO2019098351A1 (ja) 糖尿病合併症用マーカー

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS, REAGENTS, AND USES THEREOF

FGA Letters patent sealed or granted (standard patent)